{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:18:46Z","timestamp":1789683526515,"version":"4.0.1"},"reference-count":30,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Glucagon-like peptide-1 (GLP-1) agonists are widely used in the management of type 2 diabetes and obesity, with their therapeutic scope expanding to address cardiometabolic and cardiorenal conditions. However, their increasing use has been associated with potential adverse effects, including acute pancreatitis (AP). The exact prevalence of GLP-1 agonist-induced AP remains uncertain and reliable predictors for its onset have yet to be identified. We present 3 cases of class-associated predilection for GLP-1 analog-associated AP in patients with carrier states for hemochromatosis (HC) and cystic fibrosis. Case 1 is a heterozygous carrier for the C282Y HC pathogenic variant. Case 2 is a heterozygous carrier of the Delta F508 deletion of the cystic fibrosis transmembrane regulator (CFTR) gene. Case 3 is compound heterozygous carrier of a single CFTR intron 9 poly T allele pathogenic variant (5T\/7T\/8T), as well as a single pathogenic variant of the C282Y HC gene. Our observation suggests that carrier states for cystic fibrosis and HC may predispose individuals to GLP-1 agonist-associated AP. Genetic testing for these carrier states should be considered among patients with GLP-1 agonist-associated AP to provide more support and data for this as a potential true risk factor.<\/jats:p>","DOI":"10.1210\/jcemcr\/luaf104","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T07:21:42Z","timestamp":1747293702000},"source":"Crossref","is-referenced-by-count":5,"title":["Cystic Fibrosis and Hemochromatosis Carriers May Be Prone to Glucagon-like Peptide-1 Agonist Pancreatitis: 3 Cases"],"prefix":"10.1210","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9336-3350","authenticated-orcid":false,"given":"Guy Itzhak","family":"Sydney","sequence":"first","affiliation":[{"name":"Section of Endocrinology, Yale School of Medicine , New Haven, CT 06510 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy","family":"Do","sequence":"additional","affiliation":[{"name":"Dept of Medicine, Ochsner Medical Center , New Orleans, LA 70121 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Austin","family":"West","sequence":"additional","affiliation":[{"name":"Section of Pulmonology and Critical Care, University of Southern California Medical Center , Los Angeles, CA 90333 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6962-9304","authenticated-orcid":false,"given":"Gabriel Ikponmosa","family":"Uwaifo","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, Southern Illinois University School of Medicine , Springfield, IL 62702 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"issue":"39","key":"2025052400020450200_luaf104-B1","doi-asserted-by":"crossref","first-page":"7059","DOI":"10.3748\/wjg.v23.i39.7059","article-title":"Less common etiologies of exocrine pancreatic insufficiency","volume":"23","author":"Singh","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"1","key":"2025052400020450200_luaf104-B2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev.med.57.121304.131310","article-title":"Hemochromatosis: genetics and pathophysiology","volume":"57","author":"Beutler","year":"2006","journal-title":"Annu Rev Med"},{"issue":"1","key":"2025052400020450200_luaf104-B3","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s12879-017-2448-z","article-title":"Cystic fibrosis carriership and tuberculosis: hints toward an evolutionary selective advantage based on data from the Brazilian territory","volume":"17","author":"Bosch","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"3","key":"2025052400020450200_luaf104-B4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1023\/A:1022853822424","article-title":"Update and review: cystic fibrosis","volume":"8","author":"Brown","year":"1999","journal-title":"J Genet Couns"},{"issue":"suppl_6","key":"2025052400020450200_luaf104-B5","doi-asserted-by":"crossref","first-page":"vi1","DOI":"10.1136\/gut.2005.065946","article-title":"Human pancreatic exocrine response to nutrients in health and disease","volume":"54","author":"Keller","year":"2005","journal-title":"Gut"},{"issue":"1","key":"2025052400020450200_luaf104-B6","first-page":"1","article-title":"Cystic fibrosis. A WHO\/ICF(M)A meeting","volume":"63","author":"Meeting AWI","year":"1985","journal-title":"Bull World Health Organ"},{"issue":"3","key":"2025052400020450200_luaf104-B7","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1073\/pnas.1914912117","article-title":"Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions","volume":"117","author":"Miller","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2025052400020450200_luaf104-B8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.gene.2014.01.022","article-title":"Spectrum and distribution of CFTR gene mutations in asthma and chronic pancreatitis cases of North Indian population","volume":"539","author":"Muthuswamy","year":"2014","journal-title":"Gene"},{"issue":"3","key":"2025052400020450200_luaf104-B9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000102068","article-title":"Cystic fibrosis and formes frustes of CFTR-related disease","volume":"74","author":"Southern","year":"2007","journal-title":"Respiration"},{"issue":"3","key":"2025052400020450200_luaf104-B10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/aje\/154.3.193","article-title":"HFE gene and hereditary hemochromatosis: a HuGE review. Human genome epidemiology","volume":"154","author":"Hanson","year":"2001","journal-title":"Am J Epidemiol"},{"key":"2025052400020450200_luaf104-B11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejrad.2017.02.006","article-title":"R2*-relaxometry of the pancreas in patients with human hemochromatosis protein associated hereditary hemochromatosis","volume":"89","author":"Henninger","year":"2017","journal-title":"Eur J Radiol"},{"issue":"4","key":"2025052400020450200_luaf104-B12","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/jgh.12804","article-title":"Natural history of HFE simple heterozygosity for C282Y and H63D: a prospective 12-year study","volume":"30","author":"Zaloumis","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"2025052400020450200_luaf104-B13","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"issue":"1","key":"2025052400020450200_luaf104-B14","doi-asserted-by":"crossref","first-page":"8145388","DOI":"10.1155\/2024\/8145388","article-title":"Comparison of GLP-1 receptor agonists, SGLT-2 inhibitors, and DPP-4 inhibitors as an add-on drug to insulin combined with oral hypoglycemic drugs: umbrella review","volume":"2024","author":"Chai","year":"2024","journal-title":"J Diabetes Res"},{"issue":"3","key":"2025052400020450200_luaf104-B15","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eprac.2023.12.010","article-title":"A review of incretin therapies approved and in late-stage development for overweight and obesity management","volume":"30","author":"Chetty","year":"2024","journal-title":"Endocr Pract"},{"issue":"5","key":"2025052400020450200_luaf104-B16","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s11695-024-07175-8","article-title":"Glucagon-like peptide-1 receptor agonists in post-bariatric surgery patients: a systematic review and meta-analysis","volume":"34","author":"Dutta","year":"2024","journal-title":"Obes Surg"},{"issue":"2","key":"2025052400020450200_luaf104-B17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.diabres.2014.01.010","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials","volume":"103","author":"Monami","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"2025052400020450200_luaf104-B18","doi-asserted-by":"crossref","first-page":"212283","DOI":"10.7573\/dic.212283","article-title":"A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond","volume":"4","author":"Prasad-Reddy","year":"2015","journal-title":"Drugs Context"},{"issue":"6","key":"2025052400020450200_luaf104-B19","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.numecd.2023.03.023","article-title":"Glucagon-like peptide 1 receptor agonists in end-staged kidney disease and kidney transplantation: a narrative review","volume":"33","author":"Clemens","year":"2023","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"2025052400020450200_luaf104-B20","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12933-024-02500-y","article-title":"Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives","volume":"23","author":"Sawami","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2025052400020450200_luaf104-B21","first-page":"3","article-title":"Risk factors in chronic pancreatitis","volume":"47","author":"Diaconu","year":"2009","journal-title":"Rom J Intern Med"},{"issue":"8","key":"2025052400020450200_luaf104-B22","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/jhm.13357","article-title":"Clinical progress note: glucagon-like peptide-1 receptor agonists and hospitalized patients","volume":"19","author":"Ravee","year":"2024","journal-title":"J Hosp Med"},{"issue":"3","key":"2025052400020450200_luaf104-B23","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s12020-020-02223-6","article-title":"GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials","volume":"68","author":"Cao","year":"2020","journal-title":"Endocrine"},{"key":"2025052400020450200_luaf104-B24","doi-asserted-by":"crossref","first-page":"111806","DOI":"10.1016\/j.diabres.2024.111806","article-title":"The incidence of acute pancreatitis with GLP-1 receptor agonist therapy in individuals with a known history of pancreatitis","volume":"215","author":"Lomeli","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"2025052400020450200_luaf104-B25","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/MOG.0000000000001057","article-title":"Incretin mimetics and acute pancreatitis: enemy or innocent bystander?","volume":"40","author":"Pratley","year":"2024","journal-title":"Curr Opin Gastroenterol"},{"issue":"4","key":"2025052400020450200_luaf104-B26","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/17512433.2020.1736041","article-title":"Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials","volume":"13","author":"Singh","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"7","key":"2025052400020450200_luaf104-B27","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1177\/10600280231205490","article-title":"Risk of pancreatitis with incretin therapies versus thiazolidinediones in the veterans health administration","volume":"58","author":"Wilhite","year":"2024","journal-title":"Ann Pharmacother"},{"issue":"1","key":"2025052400020450200_luaf104-B28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1373\/clinchem.2007.093492","article-title":"Association of cystic fibrosis transmembrane conductance regulator (CFTR) mutation\/variant\/haplotype and tumor necrosis factor (TNF) promoter polymorphism in hyperlipidemic pancreatitis","volume":"54","author":"Chang","year":"2008","journal-title":"Clin Chem"},{"issue":"4","key":"2025052400020450200_luaf104-B29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/humu.20232","article-title":"Increased risk of idiopathic chronic pancreatitis in cystic fibrosis carriers","volume":"26","author":"Cohn","year":"2005","journal-title":"Hum Mutat"},{"issue":"1","key":"2025052400020450200_luaf104-B30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1053\/j.gastro.2010.09.046","article-title":"Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis","volume":"140","author":"Ooi","year":"2011","journal-title":"Gastroenterology"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/7\/luaf104\/63183553\/luaf104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/7\/luaf104\/63183553\/luaf104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T04:02:10Z","timestamp":1748059330000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luaf104\/8131769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,5,15]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luaf104","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,5,15]]},"article-number":"luaf104"}}